;PMID: 12412639
;source_file_1863.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..154] = [t:44..154]
;2)section:[e:158..200] = [t:158..200]
;3)section:[e:204..266] = [t:204..266]
;4)sentence:[e:270..678] = [t:270..678]
;5)sentence:[e:679..762] = [t:679..762]
;6)sentence:[e:763..853] = [t:763..853]
;7)sentence:[e:854..1012] = [t:854..1012]
;8)sentence:[e:1013..1151] = [t:1013..1151]
;9)sentence:[e:1152..1347] = [t:1152..1347]
;10)section:[e:1351..1396] = [t:1351..1396]

;section 0 Span:0..38
;Hum Exp Toxicol. 2002 Aug;21(8):453-6.
(SEC
  (FRAG (NNP:[0..3] Hum) (NNP:[4..7] Exp) (NNP:[8..15] Toxicol) (.:[15..16] .)
        (CD:[17..21] 2002) (CC:[22..29] Aug;21-LRB-) (CD:[29..30] 8)
        (-RRB-:[30..31] -RRB-) (CD:[31..35] :453) (HYPH:[35..36] -)
        (CD:[36..38] 6.)))

;sentence 1 Span:44..154
;A study of the in vitro clinical interaction between lidocaine and 
;premedications using rat liver microsomes.
;[97..106]:substance:"lidocaine"
(SENT
  (NP-HLN
    (NP
      (NP (DT:[44..45] A) (NN:[46..51] study))
      (PP (IN:[52..54] of)
        (NP
          (NP (DT:[55..58] the)
            (ADJP (FW:[59..61] in) (FW:[62..67] vitro))
            (JJ:[68..76] clinical) (NN:[77..88] interaction))
          (PP (IN:[89..96] between)
            (NP (NN:[97..106] lidocaine) (CC:[107..110] and)
                (NNS:[112..126] premedications))))))
    (VP (VBG:[127..132] using)
      (NP (NN:[133..136] rat) (NN:[137..142] liver) (NNS:[143..153] microsomes)))
    (.:[153..154] .)))

;section 2 Span:158..200
;Nagashima A, Tanak E, Inomata S, Misawa S.
(SEC
  (FRAG (NNP:[158..167] Nagashima) (NNP:[168..169] A) (,:[169..170] ,)
        (NNP:[171..176] Tanak) (NNP:[177..178] E) (,:[178..179] ,)
        (NNP:[180..187] Inomata) (NNP:[188..189] S) (,:[189..190] ,)
        (NNP:[191..197] Misawa) (NNP:[198..200] S.)))

;section 3 Span:204..266
;Institute of Community Medicine, University of Tsukuba, Japan.
(SEC
  (FRAG (NNP:[204..213] Institute) (IN:[214..216] of) (NNP:[217..226] Community)
        (NNP:[227..235] Medicine) (,:[235..236] ,) (NNP:[237..247] University)
        (IN:[248..250] of) (NNP:[251..258] Tsukuba) (,:[258..259] ,)
        (NNP:[260..265] Japan) (.:[265..266] .)))

;sentence 4 Span:270..678
;In this study, we have investigated the relationship between lidocaine 
;metabolism and premedication, i.e., psychotropic and anti-anxiety agents 
;(diazepam, midazolam), hypnotics (pentobarbital, thiamylal), depolarizing 
;muscular relaxants (vecuronium, pancuronium and suxamethonium), an active 
;anti-hypertensive (clonidine) and an H2 receptor antagonist (cimetidine)
;using  rat hepatic microsomes in vitro.
;[331..340]:substance:"lidocaine"
;[378..390]...[408..414]:substance:"psychotropic"..."agents"
;[395..414]:substance:"anti-anxiety agents"
;[417..425]:substance:"diazepam"
;[427..436]:substance:"midazolam"
;[439..448]:substance:"hypnotics"
;[450..463]:substance:"pentobarbital"
;[465..474]:substance:"thiamylal"
;[491..509]:substance:"muscular relaxants"
;[511..521]:substance:"vecuronium"
;[523..534]:substance:"pancuronium"
;[539..552]:substance:"suxamethonium"
;[566..583]:substance:"anti-hypertensive"
;[585..594]:substance:"clonidine"
;[603..614]:substance:"H2 receptor"
;[615..625]:substance:"antagonist"
;[627..637]:substance:"cimetidine"
(SENT
  (S
    (PP (IN:[270..272] In)
      (NP (DT:[273..277] this) (NN:[278..283] study)))
    (,:[283..284] ,)
    (NP-SBJ (PRP:[285..287] we))
    (VP (VBP:[288..292] have)
      (VP (VBN:[293..305] investigated)
        (NP
          (NP (DT:[306..309] the) (NN:[310..322] relationship))
          (PP (IN:[323..330] between)
            (NP
              (NP (NN:[331..340] lidocaine) (NN:[342..352] metabolism))
              (CC:[353..356] and)
              (NP
                (NP (NN:[357..370] premedication))
                (,:[370..371] ,)
                (NP
                  (ADVP (FW:[372..376] i.e.))
                  (,:[376..377] ,)
                  (NP
                    (NP
                      (NP (JJ:[378..390] psychotropic)
                        (NML-1 (-NONE-:[390..390] *P*)))
                      (CC:[391..394] and)
                      (NP
                        (NML (AFX:[395..399] anti) (HYPH:[399..400] -)
                             (NN:[400..407] anxiety))
                        (NML-1 (NNS:[408..414] agents))))
                    (NP (-LRB-:[416..417] -LRB-) (NN:[417..425] diazepam)
                        (,:[425..426] ,) (NN:[427..436] midazolam)
                        (-RRB-:[436..437] -RRB-)))
                  (,:[437..438] ,)
                  (NP
                    (NP (NNS:[439..448] hypnotics))
                    (NP (-LRB-:[449..450] -LRB-) (NN:[450..463] pentobarbital)
                        (,:[463..464] ,) (NN:[465..474] thiamylal)
                        (-RRB-:[474..475] -RRB-)))
                  (,:[475..476] ,)
                  (NP
                    (NP (VBG:[477..489] depolarizing)
                       (JJ:[491..499] muscular) (NNS:[500..509] relaxants))
                    (NP (-LRB-:[510..511] -LRB-) (NN:[511..521] vecuronium)
                        (,:[521..522] ,) (NN:[523..534] pancuronium)
                        (CC:[535..538] and) (NN:[539..552] suxamethonium)
                        (-RRB-:[552..553] -RRB-)))
                  (,:[553..554] ,)
                  (NP
                    (NP (DT:[555..557] an) (JJ:[558..564] active)
                       (AFX:[566..570] anti) (HYPH:[570..571] -)
                       (JJ:[571..583] hypertensive))
                    (NP (-LRB-:[584..585] -LRB-) (NN:[585..594] clonidine)
                        (-RRB-:[594..595] -RRB-)))
                  (CC:[596..599] and)
                  (NP
                    (NP (DT:[600..602] an)
                      (NML (NN:[603..605] H2) (NN:[606..614] receptor))
                      (NN:[615..625] antagonist))
                    (NP (-LRB-:[626..627] -LRB-) (NN:[627..637] cimetidine)
                        (-RRB-:[637..638] -RRB-))))))))
        (S-MNR
          (NP-SBJ (-NONE-:[638..638] *))
          (VP (VBG:[639..644] using)
            (NP (NN:[646..649] rat) (JJ:[650..657] hepatic)
                (NNS:[658..668] microsomes))
            (ADVP (FW:[669..671] in) (FW:[672..677] vitro))))))
    (.:[677..678] .)))

;sentence 5 Span:679..762
;Lidocaine metabolism was noncompetitively  inhibited by midazolam (Ki=29.0
;microM).
;[679..688]:substance:"Lidocaine"
;[735..744]:substance:"midazolam"
;[746..748]:quantitative-name:"Ki"
;[749..753]:quantitative-value:"29.0"
;[754..760]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1 (NN:[679..688] Lidocaine) (NN:[689..699] metabolism))
    (VP (VBD:[700..703] was)
      (ADVP-MNR (RB:[704..720] noncompetitively))
      (VP (VBN:[722..731] inhibited)
        (NP-1 (-NONE-:[731..731] *))
        (PP (IN:[732..734] by)
          (NP-LGS (NN:[735..744] midazolam)))
        (PRN (-LRB-:[745..746] -LRB-)
          (S
            (NP-SBJ (NN:[746..748] Ki))
            (VP (SYM:[748..749] =)
              (NP (CD:[749..753] 29.0) (NN:[754..760] microM))))
          (-RRB-:[760..761] -RRB-))))
    (.:[761..762] .)))

;sentence 6 Span:763..853
;Thilamylal was a moderate competitive  inhibitor of lidocaine metabolism
;(Ki=77.8 microM).
;[763..773]:substance:"Thilamylal"
;[802..811]:substance:"inhibitor"
;[815..824]:substance:"lidocaine"
;[837..839]:quantitative-name:"Ki"
;[840..844]:quantitative-value:"77.8"
;[845..851]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[763..773] Thilamylal))
    (VP (VBD:[774..777] was)
      (NP-PRD
        (NP (DT:[778..779] a) (JJ:[780..788] moderate)
            (JJ:[789..800] competitive) (NN:[802..811] inhibitor))
        (PP (IN:[812..814] of)
          (NP (NN:[815..824] lidocaine) (NN:[825..835] metabolism))))
      (PRN (-LRB-:[836..837] -LRB-)
        (S
          (NP-SBJ (NN:[837..839] Ki))
          (VP (SYM:[839..840] =)
            (NP (CD:[840..844] 77.8) (NN:[845..851] microM))))
        (-RRB-:[851..852] -RRB-)))
    (.:[852..853] .)))

;sentence 7 Span:854..1012
;Pentobarbital, diazepam and  cimetidine weakly inhibited lidocaine metabolism
;formation in a  concentration-dependent manner at high substrate
;concentrations.
;[854..867]:substance:"Pentobarbital"
;[869..877]:substance:"diazepam"
;[883..893]:substance:"cimetidine"
;[911..920]:substance:"lidocaine"
;[987..996]:substance:"substrate"
(SENT
  (S
    (NP-SBJ (NN:[854..867] Pentobarbital) (,:[867..868] ,)
            (NN:[869..877] diazepam) (CC:[878..881] and)
            (NN:[883..893] cimetidine))
    (ADVP (RB:[894..900] weakly))
    (VP (VBD:[901..910] inhibited)
      (NP
        (NML (NN:[911..920] lidocaine) (NN:[921..931] metabolism))
        (NN:[932..941] formation))
      (PP (IN:[942..944] in)
        (NP (DT:[945..946] a)
          (ADJP (NN:[948..961] concentration) (HYPH:[961..962] -)
                (JJ:[962..971] dependent))
          (NN:[972..978] manner)))
      (PP (IN:[979..981] at)
        (NP (JJ:[982..986] high) (NN:[987..996] substrate)
            (NNS:[997..1011] concentrations))))
    (.:[1011..1012] .)))

;sentence 8 Span:1013..1151
;On the other  hand, vecuronium, pancuronium, suxamethonium and clonidine did
;not inhibit  lidocaine metabolism over the therapeutic range.
;[1033..1043]:substance:"vecuronium"
;[1045..1056]:substance:"pancuronium"
;[1058..1071]:substance:"suxamethonium"
;[1076..1085]:substance:"clonidine"
;[1103..1112]:substance:"lidocaine"
(SENT
  (S
    (PP (IN:[1013..1015] On)
      (NP (DT:[1016..1019] the) (JJ:[1020..1025] other) (NN:[1027..1031] hand)))
    (,:[1031..1032] ,)
    (NP-SBJ (NN:[1033..1043] vecuronium) (,:[1043..1044] ,)
            (NN:[1045..1056] pancuronium) (,:[1056..1057] ,)
            (NN:[1058..1071] suxamethonium) (CC:[1072..1075] and)
            (NN:[1076..1085] clonidine))
    (VP (VBD:[1086..1089] did) (RB:[1090..1093] not)
      (VP (VB:[1094..1101] inhibit)
        (NP (NN:[1103..1112] lidocaine) (NN:[1113..1123] metabolism))
        (PP (IN:[1124..1128] over)
          (NP (DT:[1129..1132] the) (JJ:[1133..1144] therapeutic)
              (NN:[1145..1150] range)))))
    (.:[1150..1151] .)))

;sentence 9 Span:1152..1347
;These results show that the  interaction between lidocaine and midazolam and
;thiamylal, catalyzed by a  similar cytochrome P450, is of potential
;importance in toxicological and  clinical studies.
;[1201..1210]:substance:"lidocaine"
;[1215..1224]:substance:"midazolam"
;[1229..1238]:substance:"thiamylal"
;[1264..1279]:cyp450:"cytochrome P450"
(SENT
  (S
    (NP-SBJ (DT:[1152..1157] These) (NNS:[1158..1165] results))
    (VP (VBP:[1166..1170] show)
      (SBAR (IN:[1171..1175] that)
        (S
          (NP-SBJ
            (NP
              (NP (DT:[1176..1179] the) (NN:[1181..1192] interaction))
              (PP (IN:[1193..1200] between)
                (NP
                  (NP (NN:[1201..1210] lidocaine))
                  (CC:[1211..1214] and)
                  (NP (NN:[1215..1224] midazolam) (CC:[1225..1228] and)
                      (NN:[1229..1238] thiamylal)))))
            (,:[1238..1239] ,)
            (VP (VBN:[1240..1249] catalyzed)
              (NP (-NONE-:[1249..1249] *))
              (PP (IN:[1250..1252] by)
                (NP-LGS (DT:[1253..1254] a) (JJ:[1256..1263] similar)
                   (NN:[1264..1274] cytochrome) (NN:[1275..1279] P450)))))
          (,:[1279..1280] ,)
          (VP (VBZ:[1281..1283] is)
            (PP-PRD (IN:[1284..1286] of)
              (NP (JJ:[1287..1296] potential) (NN:[1297..1307] importance)))
            (PP (IN:[1308..1310] in)
              (NP
                (NP (JJ:[1311..1324] toxicological)
                  (NML-1 (-NONE-:[1324..1324] *P*)))
                (CC:[1325..1328] and)
                (NP (JJ:[1330..1338] clinical)
                  (NML-1 (NNS:[1339..1346] studies)))))))))
    (.:[1346..1347] .)))

;section 10 Span:1351..1396
;PMID: 12412639 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1351..1355] PMID) (::[1355..1356] :) (CD:[1357..1365] 12412639)
        (NN:[1366..1367] -LSB-) (NNP:[1367..1373] PubMed) (::[1374..1375] -)
        (NN:[1376..1383] indexed) (IN:[1384..1387] for)
        (NNP:[1388..1396] MEDLINE-RSB-)))
